Retatrutide Research Peptide — Triple Agonist, COA Verified
Retatrutide is a synthetic peptide designed as a triple receptor agonist, simultaneously targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It represents one of the most mechanistically complex metabolic research compounds currently available, and has been the subject of substantial pharmaceutical and academic investigation due to its multi-pathway approach to metabolic regulation.
Mechanism of Action
Unlike single-agonist GLP-1 compounds such as semaglutide, Retatrutide activates three distinct receptor systems in parallel. GLP-1 receptor activation contributes to appetite and glucose regulation pathways. GIP receptor activation modulates insulin signaling and nutrient metabolism. Glucagon receptor activation influences energy expenditure and lipid utilization. The simultaneous engagement of all three pathways makes Retatrutide a compound of particular interest for researchers studying integrated metabolic signaling.
Research Overview
Retatrutide has been studied in several clinical and preclinical contexts, with published research examining its effects on body weight regulation, glucose metabolism, and energy expenditure. It has attracted significant attention in metabolic disease research due to its differentiated receptor profile compared to existing GLP-1 class compounds.
Product Details
Format: Lyophilized powder | Purity: >99% | Testing: Third-party HPLC and MS verified | Packaging: Sterile sealed vial | Available in: 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg | Pricing: Single vials from $29.99 | 10-vial kits from $299.99
Storage Instructions
Store lyophilized powder in a cool, dry place prior to reconstitution. Refrigerate after reconstitution at 2–8°C. Protect from light and avoid repeated freeze-thaw cycles.
Retatrutide is intended for research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.
